Sandra M Mueller
Overview
Explore the profile of Sandra M Mueller including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
276
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wiles A, Kraft A, Mueller S, Powers C
Diagn Cytopathol
. 2019 Jan;
47(6):589-593.
PMID: 30677251
Sclerosing mucoepidermoid carcinoma with eosinophilia (SMECE) is a rare primary cancer of the thyroid. This tumor is analogous to other primary tumors of the salivary glands, breast, pancreas, and esophagus....
2.
Mueller S, Spriewald B, Bergmann S, Eismann K, Leykauf M, Korn K, et al.
J Acquir Immune Defic Syndr
. 2010 Nov;
56(2):109-17.
PMID: 21107269
Background: HIV-1 protease is subjected to dual selection pressure exerted by protease inhibitors (PIs) and cytotoxic T lymphocytes (CTL). Recently, we identified KMIGGIGGF (KF9) as a HLA-B*1501-restricted CTL epitope, including...
3.
Verheyen J, Schweitzer F, Harrer E, Knops E, Mueller S, Daumer M, et al.
Antivir Ther
. 2010 Sep;
15(6):907-12.
PMID: 20834103
Introduction: HIV type-1 (HIV-1) protease (PR) and cleavage site (CS) mutations accumulate in protease-inhibitor-resistant isolates. HIV-1 CS mutation 431V is the most frequent treatment-associated CS mutation; however, little is known...
4.
Maurer K, Harrer E, Goldwich A, Eismann K, Bergmann S, Schmitt-Haendle M, et al.
J Acquir Immune Defic Syndr
. 2008 Apr;
48(2):133-41.
PMID: 18391752
Objectives: To study the role of cytotoxic T-lymphocyte (CTL) escape for disease progression in HIV-1 infection, we analyzed the CTL response to the dominant human leukocyte antigen (HLA)-B8-restricted CTL epitope...
5.
Schneidewind A, Brockman M, Yang R, Adam R, Li B, Le Gall S, et al.
J Virol
. 2007 Sep;
81(22):12382-93.
PMID: 17804494
Human leukocyte antigen (HLA)-B27-positive subjects are uncommon in their ability to control infection with human immunodeficiency virus type 1 (HIV-1). However, late viral escape from a narrowly directed immunodominant Gag-specific...
6.
Mueller S, Schaetz B, Eismann K, Bergmann S, Bauerle M, Schmitt-Haendle M, et al.
J Virol
. 2007 Jan;
81(6):2887-98.
PMID: 17202219
To determine the influence of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cells on the development of drug resistance mutations in the HIV-1 protease, we analyzed protease sequences from...
7.
Mueller S, Jung R, Weiler S, Lang S
J Gen Virol
. 2004 Oct;
85(Pt 11):3291-3303.
PMID: 15483243
vpx genes of human immunodeficiency virus type 2 (HIV-2) and immunodeficiency viruses from macaques (SIVmac), sooty mangabeys (SIVsm) and red-capped mangabeys (SIVrcm) encode a 112 aa protein that is packed...
8.
Mueller S, Lang S
J Virol
. 2002 Oct;
76(22):11704-9.
PMID: 12388729
The highly conserved Vpr protein mediates cell cycle arrest, transcriptional transactivation, and nuclear import of the preintegration complex in human immunodeficiency virus type 1. To identify functional domains in simian...